Williams & Novak LLC Decreases Stock Holdings in AngioDynamics, Inc. $ANGO

Williams & Novak LLC reduced its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 27.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 12,455 shares of the medical instruments supplier’s stock after selling 4,755 shares during the quarter. Williams & Novak LLC’s holdings in AngioDynamics were worth $124,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in AngioDynamics by 13.5% during the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,747 shares of the medical instruments supplier’s stock valued at $166,000 after buying an additional 1,989 shares in the last quarter. Cerity Partners LLC increased its position in AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock valued at $121,000 after buying an additional 2,333 shares in the last quarter. GAMMA Investing LLC increased its position in AngioDynamics by 1,281.4% during the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 12,891 shares in the last quarter. Mackenzie Financial Corp increased its position in AngioDynamics by 20.5% during the 1st quarter. Mackenzie Financial Corp now owns 77,445 shares of the medical instruments supplier’s stock valued at $727,000 after buying an additional 13,152 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in AngioDynamics during the 1st quarter valued at about $145,000. 89.43% of the stock is owned by institutional investors and hedge funds.

Insider Activity at AngioDynamics

In related news, CEO James C. Clemmer bought 10,000 shares of the stock in a transaction dated Thursday, October 9th. The shares were purchased at an average price of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the purchase, the chief executive officer directly owned 882,529 shares of the company’s stock, valued at $9,840,198.35. This represents a 1.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.00% of the stock is owned by insiders.

AngioDynamics Stock Down 1.3%

AngioDynamics stock opened at $11.00 on Friday. AngioDynamics, Inc. has a 52 week low of $6.11 and a 52 week high of $13.50. The company has a market capitalization of $453.20 million, a price-to-earnings ratio of -14.10 and a beta of 0.78. The stock has a 50-day moving average price of $10.16 and a 200 day moving average price of $9.80.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The firm had revenue of $75.71 million for the quarter, compared to the consensus estimate of $72.69 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. The company’s revenue was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Research analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on ANGO shares. Canaccord Genuity Group upped their target price on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday. Lake Street Capital assumed coverage on AngioDynamics in a research note on Wednesday, July 16th. They issued a “buy” rating and a $24.00 price objective for the company. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of AngioDynamics in a report on Wednesday, July 16th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.